{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunomodulation&page=2",
    "query": {
      "condition": "Immunomodulation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunomodulation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T22:43:31.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01898286",
      "title": "Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "DiaPep277®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andromeda Biotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "47 Years",
        "sex": "ALL",
        "summary": "18 Years to 47 Years"
      },
      "enrollment_count": 38,
      "start_date": "2013-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-26",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01898286"
    },
    {
      "nct_id": "NCT04515329",
      "title": "Tear Film Markers in Dry Eye Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Artificial tear",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vishal Jhanji",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-12-08",
      "completion_date": "2023-12-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04515329"
    },
    {
      "nct_id": "NCT07622316",
      "title": "GAIP ASD Research Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autism",
        "ASD",
        "Autism Spectrum Disorder (ASD)"
      ],
      "interventions": [
        {
          "name": "Umbilical Cord Blood-Derived Stem Cells and Exosomes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Glutathione",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Greater Atlanta Integrative Pediatrics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-06-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Roswell, Georgia",
      "locations": [
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07622316"
    },
    {
      "nct_id": "NCT00053430",
      "title": "Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2001-04",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2009-08-07",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053430"
    },
    {
      "nct_id": "NCT00976404",
      "title": "Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "DNA + HIV-rAd5 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ART intensification (raltegravir)",
          "type": "DRUG"
        },
        {
          "name": "ART intensification (maraviroc)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Robert L. Murphy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2009-11",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-12",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00976404"
    },
    {
      "nct_id": "NCT04498208",
      "title": "Immune Modulation by Enhanced vs Standard Prehabilitation Program Before Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Surgery",
        "Immune System and Related Disorders",
        "Preoperative Care",
        "Gastrointestinal Disease",
        "Urological Disease",
        "Gynecologic Disease",
        "Thoracic Diseases"
      ],
      "interventions": [
        {
          "name": "Physical Prehabilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stress Reduction Prehabilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Prehabilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nutrition Prehabilitation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2020-10-07",
      "completion_date": "2024-04-21",
      "has_results": false,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498208"
    },
    {
      "nct_id": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Myeloid Leukemia",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Lymphoid Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-05",
      "completion_date": "2018-10-09",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643603"
    },
    {
      "nct_id": "NCT04903054",
      "title": "Selective CD28 Blockade in Renal Transplant Recipients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Renal Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Lulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-01-10",
      "completion_date": "2022-09-22",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903054"
    },
    {
      "nct_id": "NCT00001474",
      "title": "Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "1995-05",
      "completion_date": "2002-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001474"
    },
    {
      "nct_id": "NCT03107663",
      "title": "⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Positron-Emission Tomography",
        "Immunomodulation",
        "Metastatic Solid Malignancies",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "⁸⁹Zr-Df-IAB22M2C Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImaginAb, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-06-19",
      "completion_date": "2018-08-16",
      "has_results": false,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-06-25T22:43:31.855Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107663"
    }
  ]
}